Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Apr 09, 2023 11:12am
108 Views
Post# 35385784

RE:RE:RE:Mugsy boy....losing fortune

RE:RE:RE:Mugsy boy....losing fortune If this is all you are buying and if this is all you are banking on for your plan - then yes - you are a fool.

Did I sell at $10 - no.
I wouldn't have sold at $20 either - as I stated many times - this is my acquisition play.
This will continue to be my acquisition play.

My average buy is around $5.80 ... soon to drup lower.
But ... my focus has been elsewhere for the past year.

I'm comfortable with this one.
I'm getting exactly what I expected - operational growth.

And ... I continue to warn ... don't expect anything here for the share price.
A small number of people control this stock and if you don't like that - you're in the wrong place.
This control is good for ROW development.

That's all - don't fight it - enjoy it !

: )
<< Previous
Bullboard Posts
Next >>